ES2139077T3 - MEDICATION AGAINST STRESS, DEGENERATION AND AGING AND THE PROCESS FOR ITS MANUFACTURE. - Google Patents

MEDICATION AGAINST STRESS, DEGENERATION AND AGING AND THE PROCESS FOR ITS MANUFACTURE.

Info

Publication number
ES2139077T3
ES2139077T3 ES94919023T ES94919023T ES2139077T3 ES 2139077 T3 ES2139077 T3 ES 2139077T3 ES 94919023 T ES94919023 T ES 94919023T ES 94919023 T ES94919023 T ES 94919023T ES 2139077 T3 ES2139077 T3 ES 2139077T3
Authority
ES
Spain
Prior art keywords
stress
drug
enterosoluble
vitamin
aging
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES94919023T
Other languages
Spanish (es)
Inventor
Dan Riga
Sorin Riga
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Application granted granted Critical
Publication of ES2139077T3 publication Critical patent/ES2139077T3/en
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/02—Antidotes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Epidemiology (AREA)
  • Psychiatry (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Toxicology (AREA)
  • Hospice & Palliative Care (AREA)
  • Diabetes (AREA)
  • Urology & Nephrology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Addiction (AREA)
  • Reproductive Health (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Steroid Compounds (AREA)
  • Materials For Medical Uses (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

The invention relates to a new pharmacotherapeutical strategy, to an anti-stress, anti-impairment and anti-aging drug and to a process for its manufacturing. The drug has an etio-pathogenic and homeostatic action, was preclinically tested and clinically checked up in geriatric, neurologic, psychiatric and stress-dependent pathology. The drug achieves a synergistic biological, neurometabolic and cell-trophic composition, being elaborated by the association of the following active principles: a) against oxidative and catabolic stress; methionine with aminoethanol phenoxyacetates and/or aminoethyl phenoxyacetamides; b) against anabolic stress; hydroxopyrimidine carboxylates and/or oxopyrrolidine acetamides with potassium, zinc and lithium; c) vasodilative and normolipidemic; nicotinic, alcohol and/or acid, or its derivatives, with magnesium and iodine; d) energo-active and e) anti-toxic; aspartate; fructose; vitamin B1; vitamin B6; monoacid phosphate and sulfate. The process for manufacturing the drug stipulates; a) pharmaceutical preparation in two complementary types of capsules or coated tablets, gastrosoluble and enterosoluble, the last being enteric coated; b) prolonged-release of vasodilator from the enterosoluble unit.
ES94919023T 1994-06-02 1994-06-02 MEDICATION AGAINST STRESS, DEGENERATION AND AGING AND THE PROCESS FOR ITS MANUFACTURE. Expired - Lifetime ES2139077T3 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
BR9408581A BR9408581A (en) 1994-06-02 1994-06-02 Anti-stress, anti-incapacitation and anti-aging medication and process for its production
PCT/RO1994/000003 WO1995033486A1 (en) 1994-06-02 1994-06-02 Anti-stress, anti-impairment and anti-aging drug and process for manufacturing thereof

Publications (1)

Publication Number Publication Date
ES2139077T3 true ES2139077T3 (en) 2000-02-01

Family

ID=25664670

Family Applications (1)

Application Number Title Priority Date Filing Date
ES94919023T Expired - Lifetime ES2139077T3 (en) 1994-06-02 1994-06-02 MEDICATION AGAINST STRESS, DEGENERATION AND AGING AND THE PROCESS FOR ITS MANUFACTURE.

Country Status (11)

Country Link
US (1) US6174890B1 (en)
EP (1) EP0804239B1 (en)
JP (1) JP3455544B2 (en)
AT (1) ATE184490T1 (en)
AU (1) AU694125B2 (en)
BR (1) BR9408581A (en)
CA (1) CA2191837C (en)
DE (1) DE69420746T2 (en)
DK (1) DK0804239T3 (en)
ES (1) ES2139077T3 (en)
WO (1) WO1995033486A1 (en)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5703127A (en) * 1996-01-25 1997-12-30 Pak; Kyoungsik Composition, dosage unit, and method for treating stomach disorders
GB2312621B (en) * 1996-05-02 1998-03-11 Pharma Nord Uk Limited Anti-oxidant medicament
WO2000032179A2 (en) * 1998-12-01 2000-06-08 University Of Kentucky Research Foundation Use of nicotonic acid derivatives for the treatment of dna damage in skin cells
US6726939B1 (en) 2000-03-22 2004-04-27 Kyoungsik Pak Composition and method for reducing blood pressure, alleviating or eliminating angina pectoris and headaches, and enhancing skin and hair
DE10018834A1 (en) * 2000-04-15 2001-10-25 Lohmann Therapie Syst Lts Transdermal or transmucosal pharmaceutical dosage form for treatment of nicotine dependence or smoking withdrawal contains nicotine compound or substitute and CNS active compound
EA005383B1 (en) * 2001-12-28 2005-02-24 Федеральное Государственное Унитарное Предприятие "Центр Экстремальной Медицины" Method for pharmacological correction of human's efficiency under extreme conditions
US20040001817A1 (en) * 2002-05-14 2004-01-01 Giampapa Vincent C. Anti-aging nutritional supplement
AU2003264431A1 (en) * 2002-09-18 2004-04-08 Ajinomoto Co., Inc. Composition against stress-related diseases
ITRN20030021A1 (en) * 2003-07-21 2005-01-22 Ascor Chimici Srl COMPOSITION OF MATERING INCLUDING PARTICLES CONTAINING CHOLINE CHLORIDE TO BE ADMINISTERED IN RUMINALLY PROTECTED AND POST-RUMINALLY EFFECTIVE FORM.
US20050214388A1 (en) * 2004-02-18 2005-09-29 Gorham Thomas R Multivitamin formulations containing controlled-release magnesium
PL1750766T3 (en) 2004-05-11 2013-12-31 Eb Ip Lybrido B V Pharmaceutical formulations and uses thereof in the treatment of female sexual dysfunction
ITMI20041820A1 (en) * 2004-09-24 2004-12-24 Ascor Chimici Srl COMPOSITION IN MICRO-PELLETS WITH CONTROLLED RELEASE OF PHYSIOLOGICALLY ACTIVE SUBSTANCES, PREPARATION PROCEDURE AND RELATED USE IN THE ZOOTECHNICAL SECTOR.
US20060153900A1 (en) * 2005-01-13 2006-07-13 Pins Joel J Dietary supplement for treatment of lipid risk factors
US20060252831A1 (en) * 2005-05-06 2006-11-09 Christopher Offen Method for the treatment of magnesium and potassium deficiencies
US20060252830A1 (en) * 2005-05-06 2006-11-09 Brandon Stephen F Method for the treatment of magnesium and potassium deficiencies
US7998500B2 (en) * 2005-08-04 2011-08-16 Vertical Pharmaceuticals, Inc. Nutritional supplement for women
US8202546B2 (en) * 2005-08-04 2012-06-19 Vertical Pharmaceuticals, Inc. Nutritional supplement for use under physiologically stressful conditions
US7901710B2 (en) * 2005-08-04 2011-03-08 Vertical Pharmaceuticals, Inc. Nutritional supplement for use under physiologically stressful conditions
US8263137B2 (en) * 2005-08-04 2012-09-11 Vertical Pharmaceuticals, Inc. Nutritional supplement for women
EP1790343A1 (en) 2005-11-11 2007-05-30 Emotional Brain B.V. Pharmaceuticals formulations and uses thereof in the treatment of female sexual dysfunction
WO2007073006A1 (en) * 2005-12-22 2007-06-28 Keio University Inducer for increasing of content of cytoprotective amino acid and method for increasing the content
EP1925307A1 (en) 2006-11-03 2008-05-28 Emotional Brain B.V. Use of 3-alpha-androstanediol in the treatment of sexual dysfunction
JP2008174512A (en) * 2007-01-22 2008-07-31 Kracie Seiyaku Kk Composition for ameliorating exhausted feeling at time of rising
JP5788715B2 (en) * 2011-05-31 2015-10-07 キリンホールディングス株式会社 Reducing agent for oxygen consumption and energy consumption
CN109152772B (en) 2016-04-19 2021-09-28 康纳里斯研究院股份公司 Oral pharmaceutical composition of nicotinamide
WO2019161331A1 (en) * 2018-02-19 2019-08-22 Marshall Timothy M Magnesium/lithium preparations for neuroprotection and neurotrophic benefits

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3493659A (en) 1967-10-23 1970-02-03 Hoffmann La Roche Compositions and process for the production thereof

Also Published As

Publication number Publication date
JP3455544B2 (en) 2003-10-14
DE69420746D1 (en) 1999-10-21
WO1995033486A1 (en) 1995-12-14
ATE184490T1 (en) 1999-10-15
AU7010494A (en) 1996-01-04
AU694125B2 (en) 1998-07-16
EP0804239B1 (en) 1999-09-15
US6174890B1 (en) 2001-01-16
BR9408581A (en) 1997-08-26
JPH10500137A (en) 1998-01-06
DK0804239T3 (en) 2000-04-03
DE69420746T2 (en) 2000-06-29
EP0804239A1 (en) 1997-11-05
CA2191837C (en) 2002-10-15
CA2191837A1 (en) 1995-12-14

Similar Documents

Publication Publication Date Title
ES2139077T3 (en) MEDICATION AGAINST STRESS, DEGENERATION AND AGING AND THE PROCESS FOR ITS MANUFACTURE.
US20060281822A1 (en) Treatment and prevention of elevated homocysteine
US7241456B2 (en) Formulations for topical delivery of bioactive substances and methods for their use
CO6150127A2 (en) FLIBANSERINE FORMULATIONS AND METHOD TO MANUFACTURE THEM
US20070098786A1 (en) Enteric valproic acid
DE3627423A1 (en) MEDICINAL PRODUCTS CONTAINING DIPYRIDAMOL OR MOPIDAMOL AND O-ACETYLSALICYL ACID OR THEIR PHYSIOLOGICALLY COMPATIBLE SALTS, METHOD FOR THE PRODUCTION THEREOF AND THEIR USE FOR COMBATING THROMBUS FORMATION
CA2676607A1 (en) Improved stability in vitamin and mineral supplements
HRP20230809T1 (en) Treatment of alzheimer's disease in a particular patient population
US20100087546A1 (en) Use of dimethyl sulfone (msm) to reduce homocysteine levels
EE03089B1 (en) Effervescent formulation containing ibuprofen and method for its preparation
CN109430833A (en) A kind of composition and its application for improving reproduction cell vigor
IT1270239B (en) SOLID PHARMACEUTICAL COMPOSITION CONTAINING ACID (S) -2- (4- ISOBUTYLPHENYL) PROPIONIC AS ACTIVE INGREDIENT
WO2013079373A1 (en) Collagen hydrolysate and use thereof
AU2017318672A1 (en) Magnesium biotinate compositions and methods of use
CA2884592A1 (en) Compositions for improvement of brain function
JP2023030130A5 (en)
WO2002092077A2 (en) Use of lipoic acid for suppressing undesired haematological effects of chemotherapy and/or radiotherapy
FR3042411B1 (en) COMPOSITION COMPRISING A MIXTURE OF PARTICULAR MOLECULES AND USE FOR ACTING ON GLUCIDIC AND / OR LIPID METABOLISM
CA3013795A1 (en) Time release vitamins and minerals in edible oils
US20110250270A1 (en) Compositions containing a capillary-active system with application-relevant diffferentiability and their use
DE10292279D2 (en) Medicament containing an effector of glutathione metabolism together with alpha-lipoic acid in renal replacement therapy
DE102006036887B4 (en) Composition for a means of care, growth promotion and strengthening of skin, hair and nails and its use
PT2838529E (en) Composition comprising alpha- lipoic acid and honokiol for treating neuropathies
WO2012085954A1 (en) Combination comprising d-apartic acid and l-arginine or salts thereof for the improvement of cognitive activities and memory in dementia such as dementia senile and alzheimer's disease
RU2726978C2 (en) Combination of lipoic acid and taurine as osmoprotective agent

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 804239

Country of ref document: ES